Co-founder and CEO of X-Therma Xiaoxi Wei, Ph.D., holding the TimeSeal®
$22.4 million was raised in Series B funding by X-Therma, a biotechnology firm situated in San Francisco, California, that is creating a platform for organ preservation and regenerative medicine.
Leading the round were Lorea and Starling Locke Capital, with participation from both new and old investors.
By overcoming time-sensitive constraints, the company hopes to increase organ availability for transplantation by using the cash to scale up global commercial operations and facilitate development into the clinical stage with FDA breakthrough device status.
Under the direction of its CEO, Xiaoxi Wei,it is creating cold chain technology through an integrated biopreservation platform to promote regenerative medicine and provide patients in need with safe and accessible organs, modified tissues, cell and gene treatments, vaccinations, and more.
The funding will help X-Therma develop several important products, including:
- FDA Breakthrough Device designations were given to XT-ViVo® & TimeSeal® for organ preservation for transplantation
- XT-Thrive® and XT-NoVoTM for regenerative medicine and cell therapy.
About X-Therma Inc.
Via a convergent biopreservation platform, X-Therma Inc. is leading the way in innovative cold chain technologies to enhance regenerative medicine and provide patients in need with safe and accessible organs, modified tissues, cell and gene treatments, vaccines, and more. With its headquarters located in Hercules, California, and a growing presence in Austria, it is a company whose technology has the potential to revolutionize the global organ sharing and organ waiting list industry.
